FDA approves pembrolizumab as first-line combination therapy with pemetrexed and carboplatin for metastatic non-squamous NSCLC irrespective of PD-l1 expression
admin 24th May 2017 Uncategorised 0European Society for Medical Oncology News
More: FDA approves pembrolizumab as first-line combination therapy with pemetrexed and carboplatin for metastatic non-squamous NSCLC irrespective of PD-l1 expression
Source: MDlinx